NICE TA606 lanadelumab is delivering real-world outcomes that match its trial data — the benchmark berotralstat's NICE TA738 recommendation must sustain under its stop-rule review.
NICE TA606 (2019) recommended lanadelumab (Takhzyro, Takeda) for adults with three or more attacks per 12 months, with a confidential Patient Access Scheme bringing net NHS cost to an estimated £180,000–£200,000 a year. NHS commissioning runs through 40 HAE specialist centres, and real-world evidence from the UK HAE Alliance (2022–2023 survey) confirms an 87.5% reduction in mean attacks per year (from 12 before lanadelumab to 1.5 after), closely matching the HELP trial, alongside a fall in emergency attendance from 45% to 5% of patients per year. NICE's original cost-effectiveness model held within the standard £20,000–£30,000/QALY threshold with PAS, and TA606 is regarded within NHS commissioning as a rare-disease access success.
Berotralstat (Orladeyo, BioCryst) has carried a NICE recommendation since TA738 (20 October 2021), for adults with two or more attacks a month, subject to a mandatory three-month stop rule under which treatment continues only if response is demonstrated. It has been NHS-available for several years, well past the Named Patient Programme that preceded its appraisal. Its oral dosing offers a real convenience advantage over lanadelumab's four-weekly subcutaneous injection, though the two agents' evidence bases are not directly comparable: the APeX-2 trial showed a 44% attack-rate reduction versus placebo, against lanadelumab's real-world 87.5% reduction confirmed by the UK HAE Alliance. NICE's positive recommendation reflects a confidential commercial arrangement alongside the stop-rule safeguard, with the NHS acute-therapy cost offset (C1 inhibitor and icatibant rescue costs of £30,000–£80,000 a year in inadequately prophylaxed patients) forming part of the ongoing economic case for both agents.
UK HAE agent NICE and NHS status
| Drug (Brand / INN) | NICE HTA Route | NICE Recommendation & PAS | NHS Commissioning Channel | Real-World / Trial Evidence | Key Payer Risk |
|---|---|---|---|---|---|
| Takhzyro (lanadelumab) | Standard Technology Appraisal (TA606, 2019) | Recommended with confidential PAS | NHS — 40 HAE specialist centres | UK HAE Alliance 2022–2023: 87.5% attack reduction; ER attendance 45%→5% | Dominant prophylaxis; berotralstat entry pressure on share, not price |
| Orladeyo (berotralstat) | Standard Technology Appraisal (TA738, 2021) | Recommended with confidential PAS; 3-month stop rule | NHS — accessible via HAE specialist centres | APeX-2: 44% attack reduction vs placebo — not directly comparable to lanadelumab | Oral convenience vs lanadelumab; stop-rule continuation risk for non-responders |
Sources: NICE TA606 Final Appraisal Determination (lanadelumab), 2019; UK HAE Alliance real-world outcomes survey, 2023; NICE TA738 Final Appraisal Determination (berotralstat), 2021; NHS BNF pricing and NHS England HAE commissioning cost data.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- TA606 real-world evidence analysis (87.5% attack reduction, ER attendance fall from 45% to 5%)
- confidential PAS structure
- the comparator standard berotralstat's TA738 recommendation was measured against
Delivers
- NICE's indirect treatment comparison methodology behind TA738
- stop-rule mechanics and continuation criteria
- oral-vs-SC utility trade-off as assessed by NICE
Delivers
- NHS acute therapy cost benchmarking (Berinert, Firazyr) against prophylaxis net cost
- cost-offset modelling used in NICE TA606 and TA738's recommendations
- implications for future HAE submissions
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- How NHS commissioning runs through 40 HAE specialist centres, delivering an estimated £27M annual lanadelumab spend across roughly 1,500 UK patients.
- Why TA606 is regarded within NHS commissioning as a rare-disease access success, holding within the standard £20,000 to £30,000 per QALY threshold under a confidential Patient Access Scheme.
- How UK HAE Alliance real-world data from 2022 to 2023 confirms an 87.5% reduction in mean attacks per year, from 12 before lanadelumab to 1.5 after, closely matching the HELP trial.
- Why emergency attendance fell from 45% to 5% of patients a year, reinforcing the case for the £180,000 to £200,000 confidential PAS net cost.
- What TA738, dated 20 October 2021, requires: adults with 2 or more attacks a month, subject to a mandatory 3-month stop rule tied to demonstrated response.
- How the APeX-2 trial's 44% attack-rate reduction versus placebo compares, though not directly, against lanadelumab's real-world 87.5% reduction.
- Why C1 inhibitor and icatibant rescue costs of £30,000 to £80,000 a year in inadequately prophylaxed patients underpin the ongoing economic case for prophylaxis.
- How NHS acute-therapy cost offset modelling supported NICE's cost-effectiveness case for both lanadelumab's TA606 and berotralstat's TA738.
- How NHS-commissioned access to lanadelumab and berotralstat runs through the national network of 40 HAE specialist centres.
- Why berotralstat's oral dosing offers a convenience advantage over lanadelumab's four-weekly subcutaneous injection within that same access pathway.
- How Scotland's SMC and Wales's AWMSG positions on lanadelumab and berotralstat are assessed separately against NICE's TA606 precedent.
- Why devolved-nation divergence risk matters given the confidential PAS commercial arrangements underpinning both TA606 and TA738.
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
This assessment is built from NICE's published Technology Appraisal documentation, UK HAE Alliance real-world outcomes data, and NHS commissioning cost benchmarks for prophylaxis and acute HAE therapy.
Key sources: NICE TA606 Final Appraisal Determination (lanadelumab), 2019; UK HAE Alliance real-world survey, 2022–2023; NICE TA738 Final Appraisal Determination (berotralstat), 2021; NHS BNF acute-therapy pricing; NHS England HAE commissioning cost data. Devolved-nation positions (Scotland's SMC, Wales's AWMSG) are assessed separately against NICE's TA606 precedent.
- NICE TA606 recommendation and PAS status verified against the NICE TA606 Final Appraisal Determination, 2019
- Real-world attack-reduction and ER-attendance figures verified against the UK HAE Alliance real-world outcomes survey, 2022–2023
- Berotralstat's NICE recommendation verified against the NICE TA738 Final Appraisal Determination, 2021
- NHS acute-therapy cost benchmarks verified against NHS BNF pricing and NHS England HAE commissioning cost data
Frequently asked questions
Commission this assessment
AXLRx HAE Payer & HTA is built for market access, HEOR, and pricing teams navigating NICE TA606's real-world outcomes and berotralstat's NICE TA738 recommendation in the UK HAE market. Custom assessment in 72 hours.
Specify indication, payer focus (NICE TA, PAS, NHS commissioning), and commercial question.
AXLRx analyst confirms payer scope, NICE appraisal analysis, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.